This is the third post in an abstract series covering the topics at the Eagle Symposium 2015 kindly provided by Claus Bendtsen, Head of Computational Biology at AstraZeneca addressing the subject of "Driving Collaborations for Drug Discovery"
Abstract: "At AstraZeneca, we are increasingly using collaborations as a means to increase our effectiveness in drug discovery and development. In my talk you will hear some exemplars of current technology collaborations as well as our open innovation platform that will be used to demonstrate the challenges this provides in informatics and data management. We will outline the strategy taken to address these challenges and give specific examples of key projects that demonstrate this."
Speaker's Bio: Claus Bendtsen joined AstraZeneca in January 2011 as Head of Computational Biology from Novartis where he held responsibilities for modelling and biostatistics within Protein Sciences and Production. Prior to this, he spent several years with Merck & Co. providing expertise in modelling and statistics across several functional and therapeutic areas from early discovery to late development including contribution to the development of the Gardasil vaccine. Earlier in his career he co-founded three start-ups and worked in academia which included leading a centre for applied bioinformatics. He holds a Ph.D. in applied mathematics from the Danish Technical University.
Eagle Symposium 2015: Eagle Genomics organises an annual industry symposium in the promotion of innovation and advancement in genomics, bioinformatics, and computational biology to help address global issues. The Eagle Symposium 2015 builds on the theme "Bridging Biology and Informatics for R&D Innovation", taking place on 23 March 2015 at the European Bioinformatics Institute (EBI), Wellcome Trust Genome Campus in Hinxton, Cambridge, UK.